MRKMerck Sharp & Dohme LLCFinished
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
Uterine Cervical Neoplasms
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 1,060 (final count)
- Started
- May 12, 2020
- Main results expected
- Jan 7, 2025
- Fully finished
- Jan 26, 2026
- Results posted
- Jan 5, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator
Measured over: Up to approximately 55 months
Overall Survival (OS)
Measured over: Up to approximately 55 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04221945 · record last updated 2026-11-05 · checked 2026-11-09 15:47 UTC